Skip to main content

04-04-2017 | Heart failure | Article

Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?

Journal: Diabetology & Metabolic Syndrome

Authors: Anna Marcinkiewicz, Stanisław Ostrowski, Józef Drzewoski

Publisher: BioMed Central


The pathophysiology of diabetic cardiomyopathy (DC) is not fully understood. This frequently undiagnosed complication of chronic hyperglycemia leads to heart failure (HF). However, it is suggested that an appropriate metabolic control of diabetes at an early stage of this deleterious disease, is able to inhibit the development and progression of DC to HF. Recently, it has been postulated that myocardial ischaemia plays an important role in the development of this pathology. Results of the antianginal pharmacological treatment and revascularization are unsatisfactory and reveal a gap in our knowledge and current approaches to treating DC. Most recent studies emphasize the ischaemic component of DC as a key target for therapeutic strategies, which could change its unfavorable history. More stress is put on an early diagnosis of coronary artery disease (CAD), promoting prompt revascularization. Choosing the accurate time of surgical revascularization, with the inclusion of the metabolic background, can ensure complete revascularization with better prognosis. This review will focus on the complexity of DC and summarize contemporary knowledge of treatment strategies for patients with diabetes and CAD.
Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European heart journal. 2013;34(39):3035–87.CrossRefPubMed
DAI Study Group. The prevalence of coronary heart disease in type 2 diabetic patients in Italy: the DAI study. Diabet Med. 2004;21(7):738–45.CrossRef
Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol. 2002;40:946–53.CrossRefPubMed
Deb S, Singh SK, Moussa F, Tsubota H, Une D, Kiss A, et al. The long-term impact of diabetes on graft patency after coronary artery bypass grafting surgery: a substudy of the multicenter Radial Artery Patency Study. J Thorac Cardiovasc Surg. 2014;148(4):1246–53.CrossRefPubMed
Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2013;18:149–66.CrossRefPubMed
Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013;17(6):327–38.CrossRef
Ebrahimi M, Pahlavan AA, Salimi S, Khalaj M. Comparing the severity of coronary artery stenosis in diabetic and nondiabetic patients. Biotechnol Health Sci. 2014;1(1):e19189.CrossRef
Zapolski T, Kamińska A, Konarski Ł, Wysokiński A. The left atrium volume index: a biomarker of left atrium remodelling—methods of assessment and predictive value. Kardiol Pol. 2013;71(2):191–7.CrossRefPubMed
Sun Y, Hu D. The link between diabetes and atrial fibrillation: cause or correlation? J Cardiovasc Dis Res. 2010;1(1):10–1.CrossRefPubMedPubMedCentral
Shah AM, Hung CL, Shin SH, Skali H, Verma A, Ghali JK, et al. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. Am Heart J. 2011;162:685–91.CrossRefPubMed
Nitenberg A, Ledoux S, Valensi P, Sachs R, Attali JR, Antony I. Dysfunction of the coronary microcirculation in type 2 diabetic patients. Arch Mal Coeur Vaiss. 2000;93(8):937–41.PubMed
Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res. 2001;49(3):554–60.CrossRefPubMed
Kasznicki J, Drzewoski J. Heart failure in the diabetic population—pathophysiology, diagnosis and management. Arch Med Sci. 2014;10(3):546–56.CrossRefPubMedPubMedCentral
Konduracka E, Cieslik G, Galicka-Latala D, Rostoff P, Pietrucha A, Latacz P, et al. Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol. 2013;50(4):597–606.CrossRefPubMedPubMedCentral
Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11(1):31–9.CrossRefPubMedPubMedCentral
Lebeche D. Diabetic cardiomyopathy: is resistin a culprit? Cardiovasc Diagn Ther. 2015;5(5):387–93.PubMedPubMedCentral
Chemaly ER, Hadri L, Zhang S, Kim M, Kohlbrenner E, Sheng J, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol. 2011;51:144–55.CrossRefPubMedPubMedCentral
Bobbert P, Jenke A, Bobbert T, Kühl U, Rauch U, Lassner D, et al. High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. Eur J Heart Fail. 2012;14:1265–75.CrossRefPubMed
Kim M, Oh JK, Sakata S, Liang I, Park W, Hajjar RJ, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008;45:270–80.CrossRefPubMedPubMedCentral
Takata Y, Osawa H, Kurata M, Kurokawa M, Yamauchi J, Ochi M, et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension. 2008;51:534–9.CrossRefPubMed
Sato N, Kobayashi K, Inoguchi T, Sonoda N, Imamura M, Sekiguchi N, et al. Adenovirusmediated high expression of resistin causes dyslipidemia in mice. Endocrinology. 2005;146:273–9.CrossRefPubMed
Chemaly ER, Kang S, Zhang S, McCollum L, Chen J, Bénard L, et al. Differential patterns of replacement and reactive fibrosis in pressure and volume overload are related to the propensity for ischaemia and involve resistin. J Physiol. 2013;591:5337–55.CrossRefPubMedPubMedCentral
Nutter CA, Jaworski EA, Verma SK, Deshmukh V, Wang Q, Botvinnik O, et al. Dysregulation of RBFOX2 is an early event in cardiac pathogenesis of diabetes. Cell Rep. 2016;15(10):2200–13.CrossRefPubMedPubMedCentral
Delbridge LM, Benson VL, Ritchie RH, Mellor KM. Diabetic cardiomyopathy: the case for a role of fructose in disease etiology. Diabetes. 2016;65(12):3521–8.CrossRefPubMed
Li J, Ma W, Yue G, Tang Y, Kim IM, Weintraub NL, et al. Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy. J Mol Cell Cardiol. 2016;30(102):53–60.
Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, de Groote P. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol. 2003;2:1.CrossRefPubMedPubMedCentral
Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al. Bypass angioplasty revascularization investigation 2 diabetes (bari 2d) study group. The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease. Circulation. 2009;120(25):2529–40.CrossRefPubMedPubMedCentral
Kawasaki D, Kosugi K, Waki H, Yamamoto K, Tsujino T, Masuyama T, et al. Role of activated renin–angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients—reversal by chronic angiotensin II type 1A receptor blockade. Circ J. 2007;71:524–9.CrossRefPubMed
Pandey A, McGuire DK, de Lemos JA, Das SR, Berry JD, Brilakis ES, et al. Revascularization trends in patients with diabetes mellitus and multivessel coronary artery disease presenting with non-ST elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2016;9(3):197–205.CrossRefPubMed
Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2014;46(4):517–92.CrossRefPubMed
Radico F, Cicchitti V, Zimarino M, De Caterina R. Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: practical considerations for diagnostic tests. J Am Coll Cardiol Intv. 2014;7:453–63.CrossRef
Kleber ME, Goliasch G, Grammer TB, Pilz S, Tomaschitz A, Silbernagel G, et al. Evolving biomarkers improve prediction of long-term mortality in patients with stable coronary artery disease: the BIO-VILCAD score. J Intern Med. 2014;276(2):184–94.CrossRefPubMed
Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375–84.CrossRefPubMed
Park SJ, Ahn JM, Kim JH, Park DW, Yun SC, Lee JY, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;372:1204–12.CrossRefPubMed
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372:1213–22.CrossRefPubMed
Sedlis SP, Morrison DA, Lorin JD, Esposito R, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass outcome of diabetic patients in the AWESOME Randomized Trial and Registry. JACC. 2002;40(9):1555–66.CrossRefPubMed
Hoffman DM, Dimitrova KR, DeCastro H, Friedmann P, Geller CM, Ko W, et al. Improving long term outcome for diabetic patients undergoing surgical revascularization by use of the radial artery conduit: a propensity matched study. J Cardiothorac Surg. 2013;8:27.CrossRefPubMedPubMedCentral
Agrifoglio M, Trezzi M, Barili F, Dainese L, Cheema FH, Topkara VK, et al. Double vs single internal thoracic artery harvesting in diabetic patients: role in perioperative infection rate. J Cardiothorac Surg. 2008;3:35.CrossRefPubMedPubMedCentral
Hemo E, Mohr R, Uretzky G, Katz G, Popovits N, Pevni D, et al. Long-term outcomes of patients with diabetes receiving bilateral internal thoracic artery grafts. J Thorac Cardiovasc Surg. 2013;146(3):586–92.CrossRefPubMed
Milani R, Brofman PR, Guimaraes M, Barboza L, Tchaick RM, Meister Filho H, et al. Double skeletonized internal thoracic artery vs. double conventional internal thoracic artery in diabetic patients submitted to OPCAB. Rev Bras Cir Cardiovasc. 2008;23(3):351–7.CrossRefPubMed
Renner A, Zittermann A, Aboud A, Pühler T, Hakim-Meibodi K, Quester W, et al. Coronary revascularization in diabetic patients: off-pump versus on-pump surgery. Ann Thorac Surg. 2013;96(2):528–34.CrossRefPubMed
Emmert MY, Salzberg SP, Seifert B, Rodriguez H, Plass A, Hoerstrup SP, et al. Is off-pump superior to conventional coronary artery bypass grafting in diabetic patients with multivessel disease? Eur J Cardiothorac Surg. 2011;40(1):233–9.CrossRefPubMed
Trzeciak P, Foremny J, Wrobel M, Herdyńska-Wąs M, Hrapkowicz T, Szymborska-Kajaneket A, et al. New guidelines of the American Diabetes Association (ADA) emphasize the diagnostic and prognostic value of glycated haemoglobin: reasons for satisfaction for cardiac surgeons and the operated patients. Kardiochir Torakochir Pol. 2010;7(2):180–4.
Polish Society of Diabetology. Clinical recommendations concerning management of diabetic patients 2015. Clin Diabetol. 2015;4:1–73.
Pezzella AT, Holmes SD, Pritchard G, Speir AM, Ad N. Impact of perioperative glycemic control strategy on patient survival after coronary bypass surgery. Ann Thorac Surg. 2014;98(4):1281–5.CrossRefPubMed
Liou HL, Shih CC, Chung KC, Chen HI. Comparison of the effect of intensive versus conventional insulinotherapy in patients with cardiac surgery after cardiopulmonary bypass. Chin J Physiol. 2013;56(2):101–9.PubMed
Bakuy V, Unal O, Gursoy M, Kunt A, Ozisik K, Sargon M, et al. Electron microscopic evaluation of internal thoracic artery endothelial morphology in diabetic coronary bypass patients. Ann Thorac Surg. 2014;97(3):851–7.CrossRefPubMed
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8):2430–5.CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »